• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Chiromics, BMS form drug discovery alliance

Chiromics, BMS form drug discovery alliance

November 20, 2012
CenterWatch Staff

Chiromics, a drug discovery company based in Princeton, N.J., has formed a strategic research alliance with global biopharmaceutical company Bristol-Myers Squibb.

The research alliance includes grants of non-exclusive license for use of Chiromics' chemical compound library, exclusive license to a proprietary chemical compound collection and a screening collaboration to discover and optimize novel classes of small molecules against multiple therapeutic targets.

Chiromics' compound collections are assembled using Chiromics' core chemical technology referred to as "cascade catalysis." This technology was invented in the MacMillan Laboratories at Princeton University. Cascade catalysis allows for the creation of "accessible complexity," a diverse collection of molecules that is more complex than and differentiated from currently existing small molecule collections, while retaining drug-like properties, the ability to develop structure-activity relationships and ease of re-synthesis.

The synergistic combination of Chiromics' chemical compound collection of accessible complexity, and Chalis, Chiromics' exclusive hit recognition algorithm for affinity selection, enables the identification of new lead molecules that is complementary to conventional high throughput screening processes.

"We are delighted that Bristol-Myers Squibb has chosen Chiromics as a drug discovery partner based on their proven commitment to innovation and reputation as a strong collaborator with biotech companies,” said David MacMillan, Ph.D., founder of Chiromics. “This collaboration further authenticates that Chiromics' chemical technology and discovery platform is a unique gateway to a new set of small molecules for drug discovery."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing